New CGM device aims to simplify diabetes management
NCT ID NCT06904846
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing a new continuous glucose monitor (CGM) called the iCan o3 in 70 adults with type 1 or type 2 diabetes. Participants will wear the device for 60 days to see if it improves their blood sugar control, especially the time spent in a healthy range. The goal is to make diabetes management easier and reduce the need for fingerstick tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iCan o3 Continuous Glucose Monitoring (CGM) System (a device that continuously measures blood sugar levels)
What this could lead to
If successful, this could show that the iCan o3 CGM helps people with diabetes better manage their blood sugar levels and reduce fingerstick testing.
What could go wrong
This is a small, short-term study (70 people, 60 days) and may not prove long-term benefits. Risks include skin irritation and delayed glucose readings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UZA ANTWERP UZA Dienst Endocrinologie
Antwerp, Belgium